Clinical

Latest News


Latest Videos


More News

Researchers at the University of Pennsylvania's Abramson Cancer Center found combining 2 immunotherapies to be safe and elicit a clinical response in patients with metastatic melanoma.

One of the hot new cancer immunotherapy drugs, Merck & Co's Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to 3 studies presented at the American Association for Cancer Research conference.

The leading peer-reviewed journal in managed care and the world leader in diabetes research and clinical care will present the conference at the Renaissance Boston Waterfront April 16-17, 2015. Faculty presentations and panel discussions will cover clinical, behavioral and technological aspects of care for persons with type 1 and type 2 diabetes mellitus.

In a final rule (PDF) issued Thursday afternoon, HHS formally set an Oct. 1, 2015, compliance date for conversion to ICD-10 diagnostic and procedure codes, incorporating the absolute minimum delay imposed by Congress when it ordered HHS to roll back the conversion date previously set for Oct. 1, 2014.

Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests.

The American Society of Clinical Oncology's algorithm to help oncologists evaluate the clinical benefits, side effects and costs of a cancer drug or therapy will be fine-tuned over the summer and should be available for public comment by the fall, said Dr. Lowell Schnipper, chair of the society's Value in Cancer Care Task Force.

Lee Newcomer, MD, MHA, of Oncology, Genetics and Women's Health for UnitedHealthcare, says the National Comprehensive Cancer Network is transforming genetic testing by utilizing a tool called the NCCN Biomarkers Compendium, which encourages evidence-based decision-making.

Pharmacists and drug manufacturers are pushing the CMS for a one-year transition period before states attempt to implement a new formula mandated under the Patient Protection and Affordable Care Act that will significantly trim Medicaid reimbursement rates for generic drugs.

Cancer survivors often encounter a variety of health issues, the most common of which include fatigue, peripheral neuropathy, and depression. To address those specific issues, the American Society of Clinical Oncology (ASCO) has developed 3 new sets of guidelines on cancer survivorship care.

In his talk, Melanoma Guideline Update: New Agents and Opportunities for Treatment, John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center in Seattle, Washington, first showed the preferred list of treatments for advanced or metastatic melanoma: ipilimumab, vemurafenib, dabrafenib, dabrafenib plus trametinib, high-dose interleukin-2, and the drugs-to-come in the category: clinical trials.

Who should receive genetic counseling and screening for colorectal cancer (CRC)? And how early should annual colonoscopies happen once those at risk are identified? These are important questions with equally important and complex answers.

Life-saving therapies that halt cancer can take a toll on the skeletal system, leaving survivors with bone loss or more serious injuries such as broken wrists, ribs, or hips. Watchful attention, screening, and therapy are needed to prevent these outcomes.

A coalition of patient advocates, dialysis-care providers and manufacturers today will unveil a comprehensive new framework for kidney care across the country that identifies four goals: improve survival, reduce hospitalizations, improve health-related quality of life, and improve patient experience with care.